Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/99043
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial
Author: Thazhath, S.
Wu, T.
Bound, M.
Checklin, H.
Standfield, S.
Jones, K.
Horowitz, M.
Rayner, C.
Citation: American Journal of Clinical Nutrition, 2016; 103(1):66-70
Publisher: American Society for Nutrition
Issue Date: 2016
ISSN: 0002-9165
1938-3207
Statement of
Responsibility: 
Sony S Thazhath, Tongzhi Wu, Michelle J Bound, Helen L Checklin, Scott Standfield, Karen L Jones, Michael Horowitz, and Christopher K Rayner
Abstract: BACKGROUND: Resveratrol has been reported to lower glycemia in rodent models of type 2 diabetes associated with the stimulation of glucagon-like peptide 1 (GLP-1), which is known to slow gastric emptying, stimulate insulin secretion, and suppress glucagon secretion and energy intake. OBJECTIVE: We evaluated the effects of 5 wk of resveratrol treatment on GLP-1 secretion, gastric emptying, and glycemic control in type 2 diabetes. DESIGN: Fourteen patients with diet-controlled type-2 diabetes [mean ± SEM glycated hemoglobin (HbA1c): 6.4 ± 0.2% (46.4 ± 2.2 mmol/mol)] received resveratrol (500 mg twice daily) or a placebo over two 5-wk intervention periods with a 5-wk washout period in between in a double-blind, randomized, crossover design. Before and after each intervention period (4 visits), body weight and HbA1c were measured, and patients were evaluated after an overnight fast with a standardized mashed-potato meal labeled with 100 μg (13)C-octanoic acid to measure blood glucose and plasma GLP-1 concentrations and gastric emptying (breath test) over 240 min. Daily energy intake was estimated from 3-d food diaries during the week before each visit. RESULTS: Fasting and postprandial blood glucose and plasma total GLP-1 as well as gastric emptying were similar at each assessment, and the change in each variable from weeks 0 to 5 did not differ between resveratrol and placebo groups. Similarly, changes in HbA1c, daily energy intake, and body weight after 5 wk did not differ between the 2 treatments. CONCLUSIONS: In patients with diet-controlled type 2 diabetes, 5 wk of twice-daily 500 mg-resveratrol supplementation had no effect on GLP-1 secretion, glycemic control, gastric emptying, body weight, or energy intake. Our observations do not support the use of resveratrol for improving glycemic control. This trial was registered at www.anzctr.org.au as ACTRN12613000717752.
Keywords: blood glucose; GLP-1; HbA1c; incretin; resveratrol
Rights: © 2016 American Society for Nutrition
RMID: 0030039713
DOI: 10.3945/ajcn.115.117440
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.